Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…

Poxel has hit pause on its plan to file for an IPO on Nasdaq, opting instead to use its Euronext listing to generate €26.5 million to advance its Type 2…

Ionis Pharmaceuticals has sold the rights to its early-stage GI autoimmune disease candidate IONIS-JBI1-2.5Rx to Janssen as the company announces strong growth…

Merck will be giving with one hand and taking away with the other as it confirms cuts across its discovery and early-stage R&D businesses, but said it will…

Motif Bio is forging ahead with plans to list its stock on Nasdaq to raise the cash it needs to wrap up a Phase III trial of its antibiotic, iclaprim.